Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer.

Metallothioneins (MTs) are highly conserved, small molecular weight, cysteine rich proteins. The major physiological functions of metallothioneins include homeostasis of essential metals Zn and Cu and protection against cytotoxicity of heavy metals. The aim of this study was to determine whether there is an association between the -5 A/G single nucleotide polymorphism (SNP; rs28366003) in core promoter region and expression of metallothionein 2A (MT2A) gene and metal concentration in prostate cancer tissues. MT2A polymorphism was determined by the polymerase chain reaction-restriction fragment length polymorphism technique (PCR-RFLP) using 412 prostate cancer tissue samples. MT2A gene expression analysis was performed by real-time RT-PCR method. A significant association between rs28366003 genotype and MT2A expression level was found. The average mRNA level was found to be lower among minor allele carriers (the risk allele) than average expression among homozygotes for the major allele. Metal levels were analyzed by flamed atomic absorption spectrometer system. Highly statistically significant associations were detected between the SNP and Cd, Zn, Cu and Pb levels. The results of Spearman's rank correlation showed that the expressions of MT2A and Cu, Pb and Ni concentrations were negatively correlated. On the basis of the results obtained in this study, we suggest that SNP polymorphism may affect the MT2A gene expression in prostate and this is associated with some metal accumulation.

[1]  D. Giedroc,et al.  Metal response element (MRE)-binding transcription factor-1 (MTF-1): structure, function, and regulation. , 2001, Antioxidants & redox signaling.

[2]  J. Koropatnick,et al.  Signaling events for metallothionein induction. , 2003, Mutation research.

[3]  A. Schäffer,et al.  Biochemistry of metallothionein. , 1988, Biochemistry.

[4]  P. Coyle,et al.  Metallothionein: the multipurpose protein , 2002, Cellular and Molecular Life Sciences CMLS.

[5]  P. Dzięgiel Expression of metallothioneins in tumor cells. , 2004, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[6]  H. Gurer,et al.  Can antioxidants be beneficial in the treatment of lead poisoning? , 2000, Free radical biology & medicine.

[7]  B. Jiao,et al.  Metallothionein gene expression under different time in testicular Sertoli and spermatogenic cells of rats treated with cadmium. , 2003, Reproductive toxicology.

[8]  T. Rohan,et al.  Trace elements and cancer risk: a review of the epidemiologic evidence , 2007, Cancer Causes & Control.

[9]  V. Saba,et al.  Novel -209A/G MT2A Polymorphism in Old Patients with Type 2 Diabetes and Atherosclerosis: Relationship with Inflammation (IL-6) and Zinc , 2005, Biogerontology.

[10]  B. Diwan,et al.  Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  Mutsushi Yamasaki,et al.  Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. , 2007, Oncology reports.

[12]  P. Joseph Mechanisms of cadmium carcinogenesis. , 2009, Toxicology and applied pharmacology.

[13]  M. Webber,et al.  Cadmium-induced malignant transformation of human prostate epithelial cells. , 2001, Cancer research.

[14]  R. Franklin,et al.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. , 2005, Mitochondrion.

[15]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[16]  A. Daragó,et al.  Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions , 2009, BioMetals.

[17]  S. Álvarez,et al.  Morphological changes and oxidative stress in rat prostate exposed to a non-carcinogenic dose of cadmium. , 2004, Toxicology letters.

[18]  M. Stoltenberg,et al.  The role of metallothionein in oncogenesis and cancer prognosis. , 2009, Progress in histochemistry and cytochemistry.

[19]  L. Patrick Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. , 2006, Alternative medicine review : a journal of clinical therapeutic.

[20]  S. Zaichick,et al.  Trace elements of normal, benign hypertrophic and cancerous tissues of the human prostate gland investigated by neutron activation analysis. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[21]  M. Webber,et al.  Tumor Suppressor Gene Inactivation during Cadmium-Induced Malignant Transformation of Human Prostate Cells Correlates with Overexpression of de Novo DNA Methyltransferase , 2007, Environmental health perspectives.

[22]  Antonia A. Nemec,et al.  Nickel mobilizes intracellular zinc to induce metallothionein in human airway epithelial cells. , 2009, American journal of respiratory cell and molecular biology.

[23]  Z. Kayaaltı,et al.  The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels? , 2012, International Archives of Occupational and Environmental Health.

[24]  F. Karatas,et al.  Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer , 2006, Clinical chemistry and laboratory medicine.

[25]  M. Vašák Advances in metallothionein structure and functions. , 2005, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[26]  C. Nag,et al.  Familial, Environmental, and Occupational Risk Factors in Development of Amyotrophic Lateral Sclerosis , 2012, North American journal of medical sciences.

[27]  M. Kondoh,et al.  Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. , 2002, The Tohoku journal of experimental medicine.

[28]  Z. Kayaaltı,et al.  Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. , 2010, Toxicology and applied pharmacology.

[29]  M. Chatterjee,et al.  A Review of Metallothionein Isoforms and their Role in Pathophysiology , 2011, World journal of surgical oncology.

[30]  D. Winge,et al.  Distinct metal-binding configurations in metallothionein. , 1985, The Journal of biological chemistry.

[31]  Z. Kayaaltı,et al.  The potential effect of metallothionein 2A -5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. , 2011, Toxicology and applied pharmacology.

[32]  A. Kajdacsy-Balla,et al.  Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry. , 2008, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[33]  M. Bryś,et al.  Zinc and cadmium analysis in human prostate neoplasms , 2007, Biological Trace Element Research.

[34]  A. Hartwig,et al.  Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms , 2008, Archives of Toxicology.

[35]  G. Andrews,et al.  The DNA Binding Activity of Metal Response Element-binding Transcription Factor-1 Is Activated in Vivo and in Vitro by Zinc, but Not by Other Transition Metals* , 1998, The Journal of Biological Chemistry.

[36]  C. Klaassen,et al.  Relative in vitro affinity of hepatic metallothionein for metals. , 1984, Toxicology letters.

[37]  R. Franklin,et al.  Zinc as an anti-tumor agent in prostate cancer and in other cancers. , 2007, Archives of biochemistry and biophysics.

[38]  Z. Arbieva,et al.  Analysis of lead toxicity in human cells , 2012, BMC Genomics.

[39]  M. Yaman Comprehensive comparison of trace metal concentrations in cancerous and non-cancerous human tissues. , 2006, Current medicinal chemistry.

[40]  T Theophanides,et al.  Copper and carcinogenesis. , 2002, Critical reviews in oncology/hematology.

[41]  N. Miura,et al.  Potential effect on cellular response to cadmium of a single-nucleotide A → G polymorphism in the promoter of the human gene for metallothionein IIA , 2006, Human Genetics.

[42]  E. Mariani,et al.  The +838 C/G MT2A Polymorphism, Metals, and the Inflammatory/Immune Response in Carotid Artery Stenosis in Elderly People , 2007, Molecular medicine.

[43]  M. Yaman,et al.  Comparison of trace metal concentrations in malign and benign human prostate. , 2005, Journal of medicinal chemistry.

[44]  D. Breljak,et al.  Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs , 2010, BioMetals.

[45]  S. Theocharis,et al.  Expression of metallothionein in lung carcinoma: correlation with histological type and grade , 2002, Histopathology.

[46]  M. Bryś,et al.  Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. , 2012, Cancer genetics.